Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

7.220 +0.030 (+0.42%)
Streaming Delayed Price Updated: 10:20 AM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with navenibart, aiming for double-digit revenue growth. 
Via Benzinga
BioCryst To Acquire Astria Therapeutics In $700M Deal
Via Stocktwits
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
Earnings Scheduled For August 4, 2025
 
Via Benzinga
Earnings Outlook For BioCryst Pharma
 
Via Benzinga
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level
CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 
Via Stocktwits
Topics Artificial Intelligence Earnings
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) Exceeds Q2 2025 Expectations with Robust Revenue and Profit Growth
BioCryst Pharmaceuticals (BCRX) beats Q2 2025 estimates with strong revenue and profit growth, driven by ORLADEYO sales. Shares rise ~5% pre-market. 
Via Chartmill
BioCryst (BCRX) Q2 Revenue Jumps 50%
Via The Motley Fool
Earnings Scheduled For May 5, 2025
 
Via Benzinga
BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering
BioCryst sells European Orladeyo rights to Neopharmed for up to $264 million, plans to eliminate term debt and boost long-term cash position. 
Via Benzinga
BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish
As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up... 
Via Stocktwits
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria
BIOCRYST PHARMACEUTICALS (NASDAQ:BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors. 
Via Chartmill
BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria
BIOCRYST PHARMACEUTICALS (BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors. 
Via Chartmill
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish
BioCryst Pharmaceuticals raised its 2025 revenue and expense forecasts, projecting net income and positive cash flow for the year. 
Via Stocktwits
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow. 
Via Benzinga
Crude Oil Falls Over 2%; ISM Services PMI Rises In April
 
Via Benzinga
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased
BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Via The Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
BCRX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025. 
Via Benzinga
Earnings Scheduled For February 24, 2025
 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
BCRX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript
BCRX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.